Interstitial Lung Disease in a Patient Treated with Denosumab

Abstract

Denosumab is an antiresorptive agent widely used for treating osteoporosis. Atypical femur fractures, osteonecrosis of the jaw and hypocalcaemia are well-known possible adverse effects of this drug. We present, to our knowledge, the first case report in the English literature of clinically significant interstitial lung disease likely related to denosumab.

Keywords

• Interstitial lung disease
• denosumab
• osteoporosis